TTrialPathMatch Me to Trials
← Back to trials
RecruitingCardiovascular Disease

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Eligible age

35–80 yrs

Accepts

All genders

Locations

6 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).

Sponsor: Amgen

You may qualify if…

  • ✓ Age 35 to ≤ 80 years.
  • ✓ Lp(a) ≥ 200 nmol/L during screening.
  • ✓ Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
  • ✓ History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary intervention.

You may not qualify if…

  • ✕ History of coronary artery bypass graft (CABG).
  • ✕ Moderate to severe renal dysfunction.
  • ✕ Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening.
  • ✕ History of hemorrhagic stroke.
  • ✕ History of major bleeding disorder.
  • ✕ Planned cardiac surgery or arterial revascularization.
  • ✕ Severe heart failure.
  • ✕ Current, recent, or planned lipoprotein apheresis.

Where it's recruiting

Connecticut

Bridgeport

Florida

Jacksonville

Kansas

Overland Park

Pennsylvania

Philadelphia

Texas

Humble

Source: ClinicalTrials.gov · NCT07293260 · last updated 2026-04-16

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction · TrialPath